{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:31:33Z","timestamp":1788777093771,"version":"build-2803163510"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T00:00:00Z","timestamp":1677456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100009269","name":"Amyloidosis Foundation","doi-asserted-by":"publisher","award":["Donald C. Brockman Memorial Research Grant"],"award-info":[{"award-number":["Donald C. Brockman Memorial Research Grant"]}],"id":[{"id":"10.13039\/100009269","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thrombotic microangiopathy (TMA) has been reported to occur in multiple myeloma (MM) patients in association with treatment with carfilzomib, an irreversible proteasome inhibitor (PI). The hallmark of TMA is vascular endothelial damage leading to microangiopathic hemolytic anemia, platelet consumption, fibrin deposition and small-vessel thrombosis with resultant tissue ischemia. The molecular mechanisms underlying carfilzomib-associated TMA are not known. Germline mutations in the complement alternative pathway have been recently shown to portend increased risk for the development of atypical hemolytic uremic syndrome (aHUS) and TMA in the setting of allogeneic stem cell transplant in pediatric patients. We hypothesized that germline mutations in the complement alternative pathway may similarly predispose MM patients to carfilzomib-associated TMA. We identified 10 MM patients with a clinical diagnosis of TMA in the context of carfilzomib treatment and assessed for the presence of germline mutations in the complement alternative pathway. Ten, matched MM patients exposed to carfilzomib but without clinical TMA were used as negative controls. We identified a frequency of deletions in the complement Factor H genes 3 and 1 (delCFHR3-CFHR1) and genes 1 and 4 (delCFHR1-CFHR4) in MM patients with carfilzomib-associated TMA that was higher as compared to the general population and matched controls. Our data suggest that complement alternative pathway dysregulation may confer susceptibility to vascular endothelial injury in MM patients and predispose to development of carfilzomib-associated TMA. Larger, retrospective studies are needed to evaluate whether screening for complement mutations may be indicated to properly counsel patients about TMA risk with carfilzomib use.<\/jats:p>","DOI":"10.1038\/s41408-023-00802-0","type":"journal-article","created":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T05:02:39Z","timestamp":1677474159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Mutations in the alternative complement pathway in multiple myeloma patients with carfilzomib-induced thrombotic microangiopathy"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0964-0237","authenticated-orcid":false,"given":"Maria","family":"Moscvin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine Ivy","family":"Liacos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianzeng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Foteini","family":"Theodorakakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0618-8900","authenticated-orcid":false,"given":"Despina","family":"Fotiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrier","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Rowell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Houry","family":"Leblebjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eileen","family":"Regan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Czarnecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niccolo\u2019","family":"Bolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7426-8865","authenticated-orcid":false,"given":"Paul","family":"Richardson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut G.","family":"Rennke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8990-3254","authenticated-orcid":false,"given":"Meletios A.","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Efstathios","family":"Kastritis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3673-0104","authenticated-orcid":false,"given":"Giada","family":"Bianchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,27]]},"reference":[{"key":"802_CR1","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1056\/NEJMra1312353","volume":"371","author":"JN George","year":"2014","unstructured":"George JN, Nester CM. Syndromes of thrombotic microangiopathy. N Engl J Med. 2014;371:1847\u20138.","journal-title":"N Engl J Med"},{"key":"802_CR2","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1182\/blood-2014-11-611335","volume":"125","author":"ZL Al-Nouri","year":"2015","unstructured":"Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125:616\u20138.","journal-title":"Blood"},{"key":"802_CR3","first-page":"1028","volume":"4","author":"M Moscvin","year":"2021","unstructured":"Moscvin M, Ho M, Bianchi G. Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. Cancer Drug Resist. 2021;4:1028\u201346.","journal-title":"Cancer Drug Resist"},{"key":"802_CR4","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1097\/PPO.0000000000000349","volume":"25","author":"G Bianchi","year":"2019","unstructured":"Bianchi G, Anderson KC. Contribution of inhibition of protein catabolism in myeloma. Cancer J. 2019;25:11\u20138.","journal-title":"Cancer J"},{"key":"802_CR5","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. lancet Oncol. 2016;17:27\u201338.","journal-title":"lancet Oncol"},{"key":"802_CR6","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Spicka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"802_CR7","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/S0140-6736(20)30734-0","volume":"396","author":"M Dimopoulos","year":"2020","unstructured":"Dimopoulos M, Quach H, Mateos MV, Landgren O, Leleu X, Siegel DS, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study. Lancet. 2020;396:186\u201397.","journal-title":"Lancet"},{"key":"802_CR8","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817\u201325.","journal-title":"Blood"},{"key":"802_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-020-00381-4","volume":"10","author":"D Fotiou","year":"2020","unstructured":"Fotiou D, Roussou M, Gakiopoulou C, Psimenou E, Gavriatopoulou M, Migkou M, et al. Carfilzomib-associated renal toxicity is common and unpredictable: a comprehensive analysis of 114 multiple myeloma patients. Blood Cancer J. 2020;10:109.","journal-title":"Blood Cancer J"},{"key":"802_CR10","doi-asserted-by":"publisher","first-page":"e174519","DOI":"10.1001\/jamaoncol.2017.4519","volume":"4","author":"AJ Waxman","year":"2018","unstructured":"Waxman AJ, Clasen S, Hwang WT, Garfall A, Vogl DT, Carver J, et al. Carfilzomib-associated cardiovascular adverse events: a systematic review and meta-analysis. JAMA Oncol. 2018;4:e174519.","journal-title":"JAMA Oncol"},{"key":"802_CR11","doi-asserted-by":"publisher","first-page":"3443","DOI":"10.1182\/bloodadvances.2018027532","volume":"2","author":"AJ Portuguese","year":"2018","unstructured":"Portuguese AJ, Lipe B. Carfilzomib-induced aHUS responds to early eculizumab and may be associated with heterozygous CFHR3-CFHR1 deletion. Blood Adv. 2018;2:3443\u20136.","journal-title":"Blood Adv"},{"key":"802_CR12","doi-asserted-by":"publisher","first-page":"E348","DOI":"10.1002\/ajh.24447","volume":"91","author":"JC Yui","year":"2016","unstructured":"Yui JC, Van Keer J, Weiss BM, Waxman AJ, Palmer MB, D\u2019Agati VD, et al. Proteasome inhibitor associated thrombotic microangiopathy. Am J Hematol. 2016;91:E348\u201352.","journal-title":"Am J Hematol"},{"key":"802_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2016.62","volume":"6","author":"Y Chen","year":"2016","unstructured":"Chen Y, Ooi M, Lim SF, Lin A, Lee J, Nagarajan C, et al. Thrombotic microangiopathy during carfilzomib use: case series in Singapore. Blood Cancer J. 2016;6:e450.","journal-title":"Blood Cancer J"},{"key":"802_CR14","doi-asserted-by":"publisher","first-page":"1926","DOI":"10.1002\/ccr3.1214","volume":"5","author":"R Gosain","year":"2017","unstructured":"Gosain R, Gill A, Fuqua J, Volz LH, Knable MRK, Bycroft R, et al. Gemcitabine and carfilzomib induced thrombotic microangiopathy: eculizumab as a life-saving treatment. Clin Case Rep. 2017;5:1926\u201330.","journal-title":"Clin Case Rep"},{"key":"802_CR15","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clml.2020.01.016","volume":"20","author":"D Bhutani","year":"2020","unstructured":"Bhutani D, Assal A, Mapara MY, Prinzing S, Lentzsch S. Case report: carfilzomib-induced thrombotic microangiopathy with complement activation treated successfully with Eculizumab. Clin Lymphoma Myeloma Leuk. 2020;20:e155\u2013e7.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"802_CR16","doi-asserted-by":"publisher","first-page":"E218","DOI":"10.1002\/ajh.25832","volume":"95","author":"MN Nguyen","year":"2020","unstructured":"Nguyen MN, Nayernama A, Jones SC, Kanapuru B, Gormley N, Waldron PE. Proteasome inhibitor-associated thrombotic microangiopathy: a review of cases reported to the FDA adverse event reporting system and published in the literature. Am J Hematol. 2020;95:E218\u2013E22.","journal-title":"Am J Hematol"},{"key":"802_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2016.09.045","volume":"91","author":"A Ravindran","year":"2017","unstructured":"Ravindran A, Go RS, Fervenza FC, Sethi S. Thrombotic microangiopathy associated with monoclonal gammopathy. Kidney Int. 2017;91:691\u20138.","journal-title":"Kidney Int"},{"key":"802_CR18","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1182\/blood-2009-05-221549","volume":"115","author":"I Moore","year":"2010","unstructured":"Moore I, Strain L, Pappworth I, Kavanagh D, Barlow PN, Herbert AP, et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood. 2010;115:379\u201387.","journal-title":"Blood"},{"key":"802_CR19","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, et al. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N. Engl J Med. 2013;368:2169\u201381.","journal-title":"N. Engl J Med"},{"key":"802_CR20","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/sj.ki.5001581","volume":"70","author":"N Besbas","year":"2006","unstructured":"Besbas N, Karpman D, Landau D, Loirat C, Proesmans W, Remuzzi G, et al. A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney Int. 2006;70:423\u201331.","journal-title":"Kidney Int"},{"key":"802_CR21","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1182\/blood-2005-10-007252","volume":"108","author":"J Caprioli","year":"2006","unstructured":"Caprioli J, Noris M, Brioschi S, Pianetti G, Castelletti F, Bettinaglio P, et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood. 2006;108:1267\u201379.","journal-title":"Blood"},{"key":"802_CR22","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1056\/NEJMra0902814","volume":"361","author":"M Noris","year":"2009","unstructured":"Noris M, Remuzzi G. Atypical hemolytic-uremic syndrome. N Engl J Med. 2009;361:1676\u201387.","journal-title":"N Engl J Med"},{"key":"802_CR23","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1182\/blood-2013-05-501445","volume":"122","author":"S Jodele","year":"2013","unstructured":"Jodele S, Licht C, Goebel J, Dixon BP, Zhang K, Sivakumaran TA, et al. Abnormalities in the alternative pathway of complement in children with hematopoietic stem cell transplant-associated thrombotic microangiopathy. Blood. 2013;122:2003\u20137.","journal-title":"Blood"},{"key":"802_CR24","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1681\/ASN.2015040385","volume":"27","author":"F Bu","year":"2016","unstructured":"Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, et al. High-throughput genetic testing for thrombotic microangiopathies and C3 glomerulopathies. J Am Soc Nephrol. 2016;27:1245\u201353.","journal-title":"J Am Soc Nephrol"},{"key":"802_CR25","doi-asserted-by":"publisher","first-page":"2809","DOI":"10.1681\/ASN.2018070759","volume":"29","author":"F Bu","year":"2018","unstructured":"Bu F, Zhang Y, Wang K, Borsa NG, Jones MB, Taylor AO, et al. Genetic analysis of 400 patients refines understanding and implicates a new gene in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2018;29:2809\u201319.","journal-title":"J Am Soc Nephrol"},{"key":"802_CR26","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.molimm.2018.06.011","volume":"102","author":"E Goicoechea de Jorge","year":"2018","unstructured":"Goicoechea de Jorge E, Lopez Lera A, Bayarri-Olmos R, Yebenes H, Lopez-Trascasa M. Rodriguez de Cordoba S. Common and rare genetic variants of complement components in human disease. Mol Immunol. 2018;102:42\u201357.","journal-title":"Mol Immunol"},{"key":"802_CR27","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1055\/s-0034-1375296","volume":"40","author":"S Rodriguez de Cordoba","year":"2014","unstructured":"Rodriguez de Cordoba S, Hidalgo MS, Pinto S, Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin Thromb Hemost. 2014;40:422\u201330.","journal-title":"Semin Thromb Hemost"},{"key":"802_CR28","doi-asserted-by":"publisher","first-page":"106195","DOI":"10.1016\/j.leukres.2019.106195","volume":"85","author":"AJ Portuguese","year":"2019","unstructured":"Portuguese AJ, Gleber C, Passero FC Jr, Lipe B. A review of thrombotic microangiopathies in multiple myeloma. Leuk Res. 2019;85:106195.","journal-title":"Leuk Res"},{"key":"802_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.112","volume":"6","author":"A Rosenthal","year":"2016","unstructured":"Rosenthal A, Luthi J, Belohlavek M, Kort\u00fcm KM, Mookadam F, Mayo A, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016;6:e384.","journal-title":"Blood Cancer J"},{"key":"802_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cvr\/cvp315","volume":"85","author":"K Stangl","year":"2010","unstructured":"Stangl K, Stangl V. The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc. Res. 2010;85:281\u201390.","journal-title":"Cardiovasc. Res"},{"key":"802_CR31","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1038\/s41375-021-01141-4","volume":"35","author":"E Kastritis","year":"2021","unstructured":"Kastritis E, Laina A, Georgiopoulos G, Gavriatopoulou M, Papanagnou ED, Papaiakovou E, et al. Carfilzomib-induced endothelial dysfunction, recovery of proteasome activity, and prediction of cardiovascular complications: a prospective study. Leukemia. 2021;35:1418\u201327.","journal-title":"Leukemia"},{"key":"802_CR32","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/bjh.16796","volume":"193","author":"M Blasco","year":"2021","unstructured":"Blasco M, Martinez-Roca A, Rodriguez-Lobato LG, Garcia-Herrera A, Rosi\u00f1ol L, Castro P, et al. Complement as the enabler of carfilzomib-induced thrombotic microangiopathy. Br J Haematol. 2021;193:181\u20137.","journal-title":"Br J Haematol"},{"key":"802_CR33","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.bbamcr.2012.03.001","volume":"1823","author":"TM Kitzler","year":"2012","unstructured":"Kitzler TM, Papillon J, Guillemette J, Wing SS, Cybulsky AV. Complement modulates the function of the ubiquitin-proteasome system and endoplasmic reticulum-associated degradation in glomerular epithelial cells. Biochim Biophys Acta. 2012;1823:1007\u201316.","journal-title":"Biochim Biophys Acta"},{"key":"802_CR34","doi-asserted-by":"publisher","first-page":"e544","DOI":"10.1097\/MPH.0000000000000986","volume":"40","author":"A Nozawa","year":"2018","unstructured":"Nozawa A, Ozeki M, Hori T, Kawamoto N, Hirayama M, Azuma E, et al. A heterozygous CFHR3-CFHR1 gene deletion in a pediatric patient with transplant-associated thrombotic microangiopathy who was treated with Eculizumab. J Pediatr Hematol Oncol. 2018;40:e544\u2013e6.","journal-title":"J Pediatr Hematol Oncol"},{"key":"802_CR35","doi-asserted-by":"publisher","first-page":"e53830","DOI":"10.1371\/journal.pone.0053830","volume":"8","author":"EG Holliday","year":"2013","unstructured":"Holliday EG, Smith AV, Cornes BK, Buitendijk G, Jensen RA, Sim X, et al. Insights into the genetic architecture of early stage age-related macular degeneration: a genome-wide association study meta-analysis. PLoS One. 2013;8:e53830.","journal-title":"PLoS One"},{"key":"802_CR36","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1203\/PDR.0b013e3181b1bd4a","volume":"66","author":"BH Lee","year":"2009","unstructured":"Lee BH, Kwak SH, Shin JI, Lee SH, Choi HJ, Kang HG, et al. Atypical hemolytic uremic syndrome associated with complement factor H autoantibodies and CFHR1\/CFHR3 deficiency. Pediatr Res. 2009;66:336\u201340.","journal-title":"Pediatr Res"},{"key":"802_CR37","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1038\/ng1890","volume":"38","author":"AE Hughes","year":"2006","unstructured":"Hughes AE, Orr N, Esfandiary H, Diaz-Torres M, Goodship T, Chakravarthy U. A common CFH haplotype, with deletion of CFHR1 and CFHR3, is associated with lower risk of age-related macular degeneration. Nat Genet. 2006;38:1173\u20137.","journal-title":"Nat Genet"},{"key":"802_CR38","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1371\/journal.pgen.0030041","volume":"3","author":"PF Zipfel","year":"2007","unstructured":"Zipfel PF, Edey M, Heinen S, Jozsi M, Richter H, Misselwitz J, et al. Deletion of complement factor H-related genes CFHR1 and CFHR3 is associated with atypical hemolytic uremic syndrome. PLoS Genet. 2007;3:e41.","journal-title":"PLoS Genet"},{"key":"802_CR39","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1080\/07853890601097030","volume":"38","author":"GS Hageman","year":"2006","unstructured":"Hageman GS, Hancox LS, Taiber AJ, Gehrs KM, Anderson DH, Johnson LV, et al. Extended haplotypes in the complement factor H (CFH) and CFH-related (CFHR) family of genes protect against age-related macular degeneration: characterization, ethnic distribution and evolutionary implications. Ann Med. 2006;38:592\u2013604.","journal-title":"Ann Med"},{"key":"802_CR40","doi-asserted-by":"publisher","first-page":"e1002079","DOI":"10.1371\/journal.pgen.1002079","volume":"7","author":"J Zhao","year":"2011","unstructured":"Zhao J, Wu H, Khosravi M, Cui H, Qian X, Kelly JA, et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet. 2011;7:e1002079.","journal-title":"PLoS Genet"},{"key":"802_CR41","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s00467-011-1943-5","volume":"27","author":"D Provaznikova","year":"2012","unstructured":"Provaznikova D, Rittich S, Malina M, Seeman T, Marinov I, Riedl M, et al. Manifestation of atypical hemolytic uremic syndrome caused by novel mutations in MCP. Pediatr Nephrol. 2012;27:73\u201381.","journal-title":"Pediatr Nephrol"},{"key":"802_CR42","doi-asserted-by":"publisher","first-page":"E1445","DOI":"10.1002\/humu.21256","volume":"31","author":"TK Maga","year":"2010","unstructured":"Maga TK, Nishimura CJ, Weaver AE, Frees KL, Smith RJ. Mutations in alternative pathway complement proteins in American patients with atypical hemolytic uremic syndrome. Hum Mutat. 2010;31:E1445\u201360.","journal-title":"Hum Mutat"},{"key":"802_CR43","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/jhg.2012.57","volume":"57","author":"D Westra","year":"2012","unstructured":"Westra D, Vernon KA, Volokhina EB, Pickering MC, van de Kar NC, van den Heuvel LP. Atypical hemolytic uremic syndrome and genetic aberrations in the complement factor H-related 5 gene. J Hum Genet. 2012;57:459\u201364.","journal-title":"J Hum Genet"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00802-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00802-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,27]],"date-time":"2023-02-27T06:02:34Z","timestamp":1677477754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-023-00802-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,27]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["802"],"URL":"https:\/\/doi.org\/10.1038\/s41408-023-00802-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,27]]},"assertion":[{"value":"13 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Giada Bianchi: Advisory board participation (with personal payment): Pfizer, Karyopharm; Maria Moscvin, Christine Ivy Liacos: nothing to disclose. Niccol\u00f2 Bolli: advisory board participation: Janssen, GSK; honoraria for lectures: GSK, Janssen, Amgen, Takeda. Efstathios Kastritis: Honoraria from Amgen, Janssen, GSK, Pfizer, Takeda and Research Support form Janssen and Amgen. Meletios A. Dimopoulos: honoraria from participation in Advisory Boards from Amgen, BMS, Janssen, Takeda, Beigene. Helmut G. Rennke: Wolters Kluwer Author of Textbook for students, Ionis Pharmaceutical-Consultant Pathologist on IgA nephropathy. Paul Richardson: Consultancy for Oncopeptides, Celgene\/BMS, Karyopharm, Sanofi, Secura Bio, GSK, and research funding for Oncopeptides, Celgene\/BMS, Karyopharm, Takeda.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"31"}}